A highly sensitive bone marrow test could double survival rates for some groups of younger adults with Acute Myeloid Leukaemia (AML) by helping doctors identify if they might relapse up to three months earlier.
The patient-specific molecular test can detect low levels of leukaemia cells in the body, known as minimal residual disease (MRD), which when left untreated causes the disease to relapse.
The trial, published today in The Lancet Haematology and led by King’s College London, showed for…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply